一线化疗后 CA19-9 浓度是转移性结直肠癌的预后预测指标。
CA19-9 Concentration After First-line Chemotherapy Is Prognostic Predictor of Metastatic Colon Cancer.
机构信息
Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan
Department of Surgery, Kashiwa Hospital, The Jikei University School of Medicine, Chiba, Japan.
出版信息
In Vivo. 2019 Nov-Dec;33(6):2087-2093. doi: 10.21873/invivo.11708.
BACKGROUND/AIM: To evaluate whether the serum levels of CEA or CA19-9 concentration is a useful predictor of survival in patients with metastatic colon cancer (mCC).
PATIENTS AND METHODS
Between 2012 and 2015, 113 patients with mCC who underwent chemotherapy according to the Japanese Colorectal Cancer Treatment Guidelines at four Jikei University Hospitals were enrolled in this study. The two serum tumor makers, CEA and CA19-9 were measured before first-line chemotherapy and at four months thereafter.
RESULTS
Serum CA19-9 concentration at four months after first-line chemotherapy (p=0.003, HR=3.761) and first-line chemotherapy including oxaliplatin (p=0.038, HR=0.312) were independent predictors of survival in patients with mCC. By excluding the transverse colon, only serum CA19-9 concentration at four months after first-line chemotherapy (p=0.005, HR=3.660) was identified as the predictor of survival.
CONCLUSION
Serum CA19-9 concentration after first-line chemotherapy seems to be a useful predictor of survival in patients with mCC.
背景/目的：评估血清 CEA 或 CA19-9 浓度是否可作为转移性结直肠癌（mCC）患者生存的有用预测指标。
患者和方法
在 2012 年至 2015 年间，根据日本结直肠癌治疗指南在四家济慈大学医院接受化疗的 113 名 mCC 患者入组本研究。在一线化疗前和之后四个月测量两种血清肿瘤标志物 CEA 和 CA19-9。
结果
一线化疗后四个月的血清 CA19-9 浓度（p=0.003，HR=3.761）和包含奥沙利铂的一线化疗（p=0.038，HR=0.312）是 mCC 患者生存的独立预测指标。排除横结肠癌后，仅一线化疗后四个月的血清 CA19-9 浓度（p=0.005，HR=3.660）被确定为生存的预测指标。
结论
一线化疗后血清 CA19-9 浓度似乎是 mCC 患者生存的有用预测指标。
Zotero 插件